Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer

  • Fang, Ying (Department of Medical Oncology, Jiangsu Tumor Hospital) ;
  • Wang, Li (Department of Medical Oncology, Jiangsu Tumor Hospital) ;
  • Xia, Guo-Hao (Department of Medical Oncology, Jiangsu Tumor Hospital) ;
  • Shi, Mei-Qi (Department of Medical Oncology, Jiangsu Tumor Hospital)
  • Published : 2014.09.15


Objective: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). Methods: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel $125mg/m^2$ on day 1 and day 8, cisplatin $75mg/m^2$ on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. One cycle of treatment was 3 weeks, and at least two were completed in each case. Results: Of the 40 patients who participated in the study, 25 achieved partial responses (PR), 12 reached a stage of stable disease (SD), and 3 suffered progressive disease (PD). The overall response rate (ORR) was 62.5% and the disease control rate (DCR) was 92.5%. Of the 20 patients without surgery or radiotherapy, 10 achieved PR, 7 reached a stage of SD, and 3 PD. The ORR was 50.0% and the DCR was 85.0%. The median progression-free survival time (PFS) of patients without surgery or radiotherapy was 5.0 months. Of the 20 patients receiving surgery or radiotherapy, 15 had PR and 5 p had SD, with an ORR of 75.0% and a DCR of 85.0%. Specifically, the DDP arm demonstrated a significantly higher ORR than the CBP arm (100%vs 54.5%, P<0.05). Common treatment related adverse events were myelosuppression, gastrointestinal response, baldness and neurotoxicity, most of which were grade 1 to 2. Conclusion: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotheraphy for stage III/IV squamous NSCLC, and its adverse effects are tolerable.


  1. AaproMS, Minckwitz GV (2008). Molecular basis for the development of noveltaxanes in the treatment of metastatic breast cancer. Eur J Cancer Suppl, 6, 3-l1.
  2. Barlesi F, Scherpereel A, Rittmeyer A, et al. ( 2013). Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmall-cell lung cancer: AVAPERL (MO22089). J Clin Oncol, 31, 3004-11.
  3. Ciuleanu T, Brodowicz T, Zielinski C, et al(2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer, a randomised, double-blind, phase 3 study. Lancet, 374, 1432-40.
  4. Cui L, Liu XX, Jiang Y, et al (2014)Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702.
  5. Desai N, Trieu V, Damascelli B, etal. (2009). SPARC expression Correlates with tumor response to albumin-bound paclitaxel in headand neck cancerpatients. Transl Oncol, 2, 59-64.
  6. Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97.
  7. Gurses N, Topcul M (2013). The effect of abraxane on cell kinetic parameters of HeLa cells. Asian Pac J Cancer Prev, 14, 4229-33.
  8. Li XD, Han JC, Zhang YJ, et al (2013). Common variations of DNA repair genes are associated with response to platinumbased chemotherapy in NSCLCs. Asian Pac J Cancer Prev, 14, 145-8.
  9. Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6.
  10. Ozdemir O, Ozdemir P, Veral A, et al (2013). ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac J Cancer Prev, 14, 4679-83.
  11. Scagliotti GV, Parikh P, von Pawel J, et a1 (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51.
  12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
  13. Shi YK, Au JS, Thongprasert S, etal. (2014). A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 9, 154-62.
  14. Socinski MA, Langer CJ, Okamoto I, et al. (2002). Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol, 24, 314-21.
  15. Trieu V, Damascelli B, Soon-ShiongP, et al ( 2008). SPARC expressionin head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nabpaclitaxel, ABI-007 Abraxane). Washington, DC, the 97th Annual Meetingof the American Association for Cancer Research (AACR), 2006.

Cited by

  1. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer vol.31, pp.12, 2014,
  2. Protective Effect of Astragalus polysaccharides on Liver Injury Induced by Several Different Chemotherapeutics in Mice vol.15, pp.23, 2015,
  3. A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer vol.32, pp.6, 2015,
  4. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer vol.32, pp.8, 2015,
  5. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer vol.75, pp.17, 2015,
  6. DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin vol.11, pp.9, 2016,
  7. Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer vol.10, pp.2, 2017,
  8. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer pp.1573-0646, 2017,
  9. Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons vol.13, pp.6, 2017,
  10. Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer vol.7, pp.5, 2017,
  11. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis vol.47, pp.1, 2019,